Dianthus Therapeutics Inc Stock Price, News & Analysis

Dianthus Therapeutics (Nasdaq: DNTH) presented new Phase 2 MaGic and preclinical data for claseprubart at the AANEM Annual Meeting and a virtual industry forum on Oct 29, 2025. Key clinical findings include an open-label extension (OLE) MG-ADL decline of -2.5 points at week 4 and a QMG reduction of -3.2 points for placebo-arm patients who received two 600mg/4mL Q2W doses. A post hoc subgroup with baseline QMG ≥10 showed a 3-point MG-ADL treatment difference for 300mg/2mL Q2W versus placebo. In vitro data suggested upstream (active C1s) inhibition may better prevent pro-inflammatory split products C3a/C3b versus C5 inhibition. Dianthus plans a Phase 3 gMG trial with two claseprubart arms (300mg/2mL Q2W and 300mg/2mL Q4W) versus placebo, anticipated to initiate in 2026.

Dianthus Therapeutics (Nasdaq: DNTH) entered an exclusive worldwide (ex-Greater China) license for DNTH212 from Leads Biolabs (LBL-047), a bifunctional BDCA2 & BAFF/APRIL inhibitor designed for severe autoimmune diseases.

Key facts: IND cleared by FDA in September 2025; Phase 1 expected to start in Q4 2025 with healthy-volunteer topline in 2H 2026. Dianthus paid $30M upfront/near-term and may pay up to $962M in milestones plus royalties. Pro forma cash ~$525M, company reaffirms runway into 2028.

Dianthus Therapeutics (NASDAQ:DNTH) announced upcoming presentations of its Phase 2 MaGic trial results for claseprubart in treating generalized Myasthenia Gravis (gMG) at the AANEM Annual Meeting in San Francisco. The presentations will take place on October 29, 2025.

The company will feature an oral presentation of the trial results during the MGFA Scientific Session and host a virtual industry forum titled "Upstream Targeting: Rethinking MG Treatment Through Active C1s Inhibition" featuring an expert panel of medical professionals. The forum will focus on the potential benefits of upstream inhibition in gMG treatment.

Dianthus Therapeutics (NASDAQ: DNTH), a clinical-stage biotech company, has successfully closed its upsized public offering, raising approximately $288 million in gross proceeds. The offering included 7,627,879 shares of common stock at $33.00 per share, with underwriters fully exercising their option for an additional 1,140,000 shares.

The company also offered pre-funded warrants for 1,112,121 shares at $32.999 per warrant with a $0.001 exercise price. The proceeds will support Dianthus's preclinical and clinical development activities, working capital, and general corporate purposes. The offering was managed by Jefferies, TD Cowen, Evercore ISI, and Stifel, with LifeSci Capital as lead manager.

Dianthus Therapeutics (NASDAQ:DNTH), a clinical-stage biotech company, has announced the pricing of its upsized public offering at $33.00 per share. The offering consists of 6,487,879 shares of common stock and pre-funded warrants to purchase up to 1,112,121 shares at $32.999 per warrant.

The offering is expected to generate approximately $251 million in gross proceeds before expenses. The company has granted underwriters a 30-day option to purchase up to an additional 1,140,000 shares. The proceeds will support Dianthus's preclinical and clinical development activities, working capital, and general corporate purposes. The offering is expected to close on September 11, 2025.

Dianthus Therapeutics (NASDAQ:DNTH), a clinical-stage biotech company focused on antibody complement therapeutics, has announced a proposed $150 million underwritten public offering of common stock and pre-funded warrants. The company will grant underwriters a 30-day option to purchase up to an additional $22.5 million of common stock.

The offering, led by joint book-running managers Jefferies, TD Cowen, Evercore ISI, and Stifel, will be conducted through a shelf registration statement effective since October 2024. Proceeds will support Dianthus's preclinical and clinical development activities, working capital, and general corporate purposes.

Dianthus Therapeutics (NASDAQ:DNTH) reported positive Phase 2 MaGic trial results for claseprubart (DNTH103) in treating generalized Myasthenia Gravis (gMG). Both 300mg and 600mg doses administered every two weeks showed statistically significant improvements in key efficacy measures.

The trial demonstrated rapid and sustained effectiveness starting from Week 1, with significant improvements in MG-ADL and QMG scores through Week 13. The 300mg dose proved equally effective as 600mg, supporting a convenient single-dose administration via subcutaneous autoinjector every two weeks.

Importantly, claseprubart showed a favorable safety profile with no serious infections, autoimmune symptoms, or drug-related serious adverse events. The company plans to initiate a Phase 3 gMG trial in 2026.

Dianthus Therapeutics (Nasdaq: DNTH) has scheduled a conference call and webcast for September 8, 2025 at 8:00 a.m. EDT to discuss results from their Phase 2 MaGic trial of claseprubart (DNTH103) in generalized Myasthenia Gravis (gMG).

The clinical-stage biotechnology company, focused on developing next-generation antibody complement therapeutics for severe autoimmune diseases, will host the event with a Q&A session for registered participants. Investors can access the webcast through the company's website, with a replay available afterward.

Dianthus Therapeutics (NASDAQ:DNTH) reported Q2 2025 financial results and business updates, highlighting significant progress in its clinical programs. The company's lead drug candidate claseprubart (DNTH103) is advancing in multiple trials:

The Phase 2 MaGic trial in generalized Myasthenia Gravis (gMG) completed enrollment with 65 patients, with top-line results expected in September 2025. The Phase 3 CAPTIVATE trial in CIDP and Phase 2 MoMeNtum trial in MMN are progressing with results anticipated in 2H'26.

Financially, Dianthus reported $309.1 million in cash, providing runway into 2H'27. Q2 net loss was $31.6 million ($0.88 per share), with R&D expenses of $26.3 million and G&A expenses of $8.9 million.